pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›CABERGOLINE
drug
save

CABERGOLINE

Marketedupdated 3mo ago
by Ingenus Pharmaceuticals LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval18 co-mentions · 9 sources
  • tagSmall Molecule9 co-mentions · 9 sources
  • companyStrides Pharma Inc6 co-mentions · 6 sources

all catalysts(9)

approval · 9
Dec 29, 2005
approval
21y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Jan 25, 2007
approval
20y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Jun 4, 2008
approval
18y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Oct 26, 2011
approval
15y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Aug 1, 2018
approval
8y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Dec 13, 2019
approval
7y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Dec 13, 2019
approval
7y ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Dec 11, 2025
approval
8mo ago
CABERGOLINE — FDA approval
CABERGOLINE
→
Mar 18, 2026
approval
5mo ago
CABERGOLINE — FDA approval
CABERGOLINE
→
view all 9 catalysts →

Trials studying CABERGOLINE

  • phase1A Study on Bioequivalence of Cabergoline Tablets in Human Bodyactive not recruitingn=72
  • phase3A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tabletsrecruitingn=382
  • phase4Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studiescompletedn=337

News(0)

no news has mentioned this drug yet

brand
CABERGOLINE
generic
CABERGOLINE
indication
Hyperprolactinaemia
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 33m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?